# Biyopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biyopharma

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Latest round: Angel (Apr 26, 2024)
- Investors on record: 3

## About

Established in 2021 and based in Hangzhou, China, Biyopharma is an innovative drug discovery company for neurological diseases. The company's founding team has more than 20 years of experience in developing innovative drugs for neurological diseases. 

The company’s main business is the research and development of innovative pharmaceuticals aimed at neurological diseases. The company’s self-developed products are focused on providing advanced treatment options for conditions such as episodic migraines and chronic migraines. Its products are used in the field of neurology.

The company generates revenue by providing innovative drugs for neurological diseases.

In January 2026, Biyopharma raised nearly CNY 100 million in Pre-A funding led by returning investor Lapam Capital, with participation from new investors Shanghai Healthcare Capital and HangZhou Capital.

## Funding rounds

- Angel, Apr 26, 2024 — Triwise Capital, Tailong VC, Chuanhua Capital

## Investors

- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Angel
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Angel
- Chuanhua Capital — Angel